# Neuronetics, Inc.: overview STIM · Nasdaq · CIK 1227636 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/stim.md) · [Financials](/companies/stim/financials.md) · [Filings](/companies/stim/filings.md) · [Insiders](/companies/stim/insiders.md) Latest reported revenue: [$41.6m](/filings/0001104659-26-094078.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-094078). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [18.5](/filings/0001104659-25-105924.md) | [22.5 d](/filings/0001104659-26-029004.md) | [32.0](/filings/0001104659-26-055322.md) | [38.1](/filings/0001104659-26-094078.md) | [37.3](/filings/0001104659-25-105924.md) | [41.8 d](/filings/0001104659-26-029004.md) | [34.5](/filings/0001104659-26-055322.md) | [41.6](/filings/0001104659-26-094078.md) | | Gross margin | % | [75.6%](/filings/0001104659-25-105924.md) | [66.2% d](/filings/0001104659-26-029004.md) | [49.2%](/filings/0001104659-26-055322.md) | [46.6%](/filings/0001104659-26-094078.md) | [45.9%](/filings/0001104659-25-105924.md) | [52.0% d](/filings/0001104659-26-029004.md) | [46.9%](/filings/0001104659-26-055322.md) | [51.1%](/filings/0001104659-26-094078.md) | | Operating margin | % | [(41.7%)](/filings/0001104659-25-105924.md) | [(51.0%) d](/filings/0001104659-26-029004.md) | [(34.4%)](/filings/0001104659-26-055322.md) | [(21.1%)](/filings/0001104659-26-094078.md) | [(19.6%)](/filings/0001104659-25-105924.md) | [(12.1%) d](/filings/0001104659-26-029004.md) | [(26.1%)](/filings/0001104659-26-055322.md) | [(3.6%)](/filings/0001104659-26-094078.md) | | Net margin | % | [(72.0%)](/filings/0001104659-25-105924.md) | [(56.3%) d](/filings/0001104659-26-029004.md) | [(39.6%)](/filings/0001104659-26-055322.md) | [(26.6%)](/filings/0001104659-26-094078.md) | [(24.3%)](/filings/0001104659-25-105924.md) | [(17.1%) d](/filings/0001104659-26-029004.md) | [(31.3%)](/filings/0001104659-26-055322.md) | [(8.3%)](/filings/0001104659-26-094078.md) | | Diluted EPS | $ per share | [(0.44)](/filings/0001104659-25-105924.md) | not reported | [(0.21)](/filings/0001104659-26-055322.md) | [(0.15)](/filings/0001104659-26-094078.md) | [(0.13)](/filings/0001104659-25-105924.md) | not reported | [(0.16)](/filings/0001104659-26-055322.md) | [(0.05)](/filings/0001104659-26-094078.md) | | Free cash flow | $m | [(5.8) d](/filings/0001104659-25-105924.md) | [(8.7) d](/filings/0001104659-26-029004.md) | [(17.2)](/filings/0001104659-26-055322.md) | [(3.8) d](/filings/0001104659-26-094078.md) | [(0.9) d](/filings/0001104659-25-105924.md) | [0.7 d](/filings/0001104659-26-094078.md) | [(9.6)](/filings/0001104659-26-055322.md) | [(1.4) d](/filings/0001104659-26-094078.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [55.3](/filings/0001558370-24-002772.md) | [65.2](/filings/0001558370-25-003833.md) | [71.3](/filings/0001104659-26-029004.md) | [74.9](/filings/0001104659-26-029004.md) | [149](/filings/0001104659-26-029004.md) | | Gross margin | % | [78.9%](/filings/0001558370-24-002772.md) | [76.3%](/filings/0001558370-25-003833.md) | [72.5%](/filings/0001104659-26-029004.md) | [72.3%](/filings/0001104659-26-029004.md) | [48.5%](/filings/0001104659-26-029004.md) | | Operating margin | % | [(49.8%)](/filings/0001558370-24-002772.md) | [(53.8%)](/filings/0001558370-25-003833.md) | [(42.8%)](/filings/0001104659-26-029004.md) | [(46.2%)](/filings/0001104659-26-029004.md) | [(21.1%)](/filings/0001104659-26-029004.md) | | Net margin | % | [(56.4%)](/filings/0001558370-24-002772.md) | [(57.0%)](/filings/0001558370-25-003833.md) | [(42.3%)](/filings/0001104659-26-029004.md) | [(58.4%)](/filings/0001104659-26-029004.md) | [(26.1%)](/filings/0001104659-26-029004.md) | | Diluted EPS | $ per share | [(1.22)](/filings/0001558370-24-002772.md) | [(1.38)](/filings/0001558370-25-003833.md) | [(1.05)](/filings/0001104659-26-029004.md) | [(1.38)](/filings/0001104659-26-029004.md) | [(0.59)](/filings/0001104659-26-029004.md) | | Free cash flow | $m | [(30.3)](/filings/0001558370-24-002772.md) | [(34.0)](/filings/0001558370-25-003833.md) | [(34.4)](/filings/0001104659-26-029004.md) | [(32.5)](/filings/0001104659-26-029004.md) | [(21.2)](/filings/0001104659-26-094078.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/stim/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Madryn Asset Management, LP](/funds/1787423.md) | 2026-06-30 | $24.1m | 18,540,488 | | Added +64,595 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $3.0m | 2,279,099 | | Reduced −591,499 | | [WEXFORD CAPITAL LP](/funds/1048462.md) | 2026-06-30 | $2.6m | 2,002,625 | | Added +1,301,664 | | [FourWorld Capital Management LLC](/funds/1770525.md) | 2026-06-30 | $2.3m | 1,744,142 | | Added +254,820 | | [Lane Generational LLC](/funds/1901384.md) | 2026-06-30 | $2.1m | 1,633,372 | | Reduced −141,252 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.0m | 1,507,097 | | Reduced −540,878 | | [MASTERS CAPITAL MANAGEMENT LLC](/funds/1104186.md) | 2026-06-30 | $1.3m | 1,000,000 | | Unchanged | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $965.6k | 742,795 | | Added +125,602 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $911.5k | 701,182 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $775.6k | 596,622 | | Reduced −1,721,915 | ## Recent filings [All 708 filings](/companies/stim/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-24 | 20:03 ET | [SCHEDULE 13D/A](/filings/0000921895-26-002299.md) | Ownership report, active investor, amended | 0000921895-26-002299 | | 2026-08-17 | 16:10 ET | [8-K](/filings/0001193125-26-354051.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-354051 | | 2026-08-11 | 16:26 ET | [10-Q](/filings/0001104659-26-094078.md) | Quarterly report, period 2026-06-30 | 0001104659-26-094078 | | 2026-08-11 | 08:05 ET | [8-K](/filings/0001193125-26-343474.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-343474 | | 2026-08-04 | 08:00 ET | [SCHEDULE 13D/A](/filings/0001193805-26-001017.md) | Ownership report, active investor, amended | 0001193805-26-001017 | | 2026-07-20 | 16:10 ET | [8-K](/filings/0001193125-26-308921.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-308921 | | 2026-06-23 | 16:38 ET | [8-K](/filings/0001193125-26-279601.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-279601 | | 2026-05-29 | 16:45 ET | [8-K](/filings/0001193125-26-248525.md) | 5.07 Shareholder vote results | 0001193125-26-248525 | | 2026-05-27 | 10:33 ET | [SCHEDULE 13D/A](/filings/0000921895-26-001483.md) | Ownership report, active investor, amended | 0000921895-26-001483 | | 2026-05-22 | 07:30 ET | [8-K](/filings/0001193125-26-235481.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-235481 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-029004.md), filed Mar 17, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/22c6f635-e4be-42ea-8211-0d4db1baea16) ## About the filer - CIK: 1227636 - Tickers: STIM - Exchange: Nasdaq - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.